Alzheimer's Immune Switch, Pancreatic Cancer Doubles Survival & Gravitational Mass Gap
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Alzheimer's Immune Switch, Pancreatic Cancer Doubles Survival & Gravitational Mass Gap
-
ナレーター：
-
著者：
(00:01:01) Forty-Eight New Alzheimer's Genes
(00:01:50) USC cPLA2 Inhibitor Discovery
(00:02:44) Pancreatic Cancer Drug Doubles Survival
(00:03:16) Precision Sparing in Breast and Lung Cancer
(00:04:05) Gravitational Waves Confirm Mass Gap
Three separate research teams — at Scripps Research, a massive genetics consortium, and USC — have independently arrived at the same conclusion: neuroinflammation, not amyloid, may be the central mechanism driving Alzheimer's disease. Scripps identified a molecular switch inside the STING protein (S-nitrosylation at cysteine-148) that locks the brain into chronic inflammation; blocking it protected synapses in mouse models. Separately, the largest Alzheimer's genetic study ever conducted identified 48 previously unknown risk genes — bringing the confirmed total to 127 — and the new genes point squarely toward immunity pathways. At USC, a computational screen of billions of molecules found a cPLA2 inhibitor that crosses the blood-brain barrier and reduces inflammation in human brain cells, with particular relevance for APOE4 carriers.
In oncology, the news is equally significant. At ASCO 2026, Revolution Medicines reported that daraxonrasib — a targeted pill for metastatic pancreatic cancer — nearly doubled survival versus standard chemotherapy, a result that stands apart from the incremental gains typical in this disease. Two further results underscore the shift toward precision oncology: the Prosigna genomic test can now spare more than 5,000 UK breast cancer patients annually from unnecessary chemotherapy, and ivonescimab, a bispecific antibody, outperformed standard immunotherapy in advanced squamous non-small cell lung cancer in the Lancet-published HARMONI-6 trial.
Finally, the LIGO-Virgo-KAGRA gravitational wave collaboration confirmed a predicted black-hole mass gap, constraining the nuclear physics of helium burning in massive stars — a decades-in-the-making theoretical confirmation.
All stories are evidence-based, caveats included. A YesWee production.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません